The briefing
Health Canada approved elinzanetant (Lynkuet) to treat moderate to severe hot flashes and night sweats in breast cancer patients. The decision follows an initial 2025 approval for treating vasomotor symptoms in women.
Original headline
Health Canada approves drug that treats hot flashes for use by breast cancer patients